Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Change in Cash: 2020-2025

Historic Change in Cash for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $19.1 million.

  • Tango Therapeutics' Change in Cash rose 1105.18% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 183.16%. This contributed to the annual value of $2.3 million for FY2024, which is 60.87% down from last year.
  • As of Q3 2025, Tango Therapeutics' Change in Cash stood at $19.1 million, which was up 199.51% from -$19.2 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Change in Cash registered a high of $154.1 million during Q3 2021, and its lowest value of -$62.2 million during Q4 2021.
  • Its 3-year average for Change in Cash is -$277,545, with a median of -$3.3 million in 2023.
  • Examining YoY changes over the last 5 years, Tango Therapeutics' Change in Cash showed a top increase of 9,825.87% in 2021 and a maximum decrease of 59,672.68% in 2021.
  • Over the past 5 years, Tango Therapeutics' Change in Cash (Quarterly) stood at -$62.2 million in 2021, then soared by 35.17% to -$40.3 million in 2022, then spiked by 119.46% to $7.9 million in 2023, then skyrocketed by 108.63% to $16.4 million in 2024, then soared by 1,105.18% to $19.1 million in 2025.
  • Its Change in Cash was $19.1 million in Q3 2025, compared to -$19.2 million in Q2 2025 and -$11.1 million in Q1 2025.